GYN Surgical Division Likely to Drive Hologic's Q2 Earnings

Hologic, Inc.’s (HOLX)   fiscal 2025 second-quarter financial results, set to release on May 1 after the market closes, will likely see a solid performance of its GYN Surgical segment driven by its International strength. Molecular Diagnostics performance is expected to have strongly contributed to the Diagnostics division’s growth. In Breast Health, steady service revenues are expected to have helped offset the capital equipment softness.Meanwhile, check out our analysis to determine if the stock is worth ...